BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Raguneprocel (Amchepry) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Raguneprocel (Amchepry)\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06482268-8718@assetmemo.bio
DTSTAMP:20261121T005444Z
DTSTART;VALUE=DATE:20271228
DTEND;VALUE=DATE:20271229
SUMMARY:Raguneprocel (Amchepry): Phase 1 readout est. (NCT06482268)
DESCRIPTION:Raguneprocel (Amchepry)\, phase 1\, Parkinson's Disease.\nStudy
 : Transplantation of Human iPS Cell-derived Dopaminergic Progenitors (CT1-
 DAP001) for Parkinson's Disease (Phase I/II)\nEstimated primary completion
 : 28 December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/r
 aguneprocel-amchepry#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06482268
URL:https://assetmemo.bio/drug/raguneprocel-amchepry#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06753331-8718@assetmemo.bio
DTSTAMP:20261121T005444Z
DTSTART;VALUE=DATE:20301215
DTEND;VALUE=DATE:20301216
SUMMARY:Raguneprocel (Amchepry): Phase 1/2 readout est. (NCT06753331)
DESCRIPTION:Raguneprocel (Amchepry)\, phase 1/2\, Parkinson's Disease.\nStu
 dy: A Multicenter Study to Evaluate Safety\, Tolerability\, and Clinical R
 esponses of DSP-1083 Into Subjects With Parkinson's Disease\nEstimated pri
 mary completion: 15 December 2030. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/raguneprocel-amchepry#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06753331
URL:https://assetmemo.bio/drug/raguneprocel-amchepry#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
